Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York, USA. With a history spanning more than 160 years, BMS has been at the forefront of developing innovative medicines to treat some of the world's most serious diseases, including cancer, cardiovascular disease, immunological disorders, and more. The company focuses on delivering life-saving medications that significantly improve patients' quality of life.
BMS is committed to advancing scientific research, conducting clinical trials, and collaborating with partners around the world to bring breakthroughs in immunotherapy, oncology, hematology, and cardiovascular care. The company’s core mission is to discover, develop, and deliver transformational medicines to patients through its diversified product pipeline.
CEO and Founder of Bristol-Myers Squibb
Bristol-Myers Squibb was formed through the merger of two pharmaceutical giants: Bristol-Myers Company (founded by William McLaren Bristol and John Ripley Myers in 1887) and Squibb Corporation (founded by Edward Robinson Squibb in 1858). The company has undergone significant changes and expansions since then, but its commitment to science and innovation remains intact.
The current CEO of Bristol-Myers Squibb is Giovanni Caforio, who assumed the role in May 2015. Under his leadership, BMS has strengthened its focus on innovative medicines, particularly in oncology and immunology. Caforio has led the company’s efforts to grow through strategic acquisitions, partnerships, and innovative research, making BMS one of the world’s most influential biopharmaceutical companies.
List of Top Companies Under Bristol-Myers Squibb
Over the years, Bristol-Myers Squibb has acquired several key companies that complement its mission of providing life-saving treatments and expanding its biopharmaceutical portfolio. Below is a list of major companies and subsidiaries under BMS, along with their approximate valuations:
| Company Name | Year Acquired/Founded | Valuation | Industry |
|---|---|---|---|
| Celgene Corporation | 2019 (Acquired) | $74 Billion | Biopharmaceuticals |
| MyoKardia | 2020 (Acquired) | $13.1 Billion | Cardiovascular Medicines |
| IFM Therapeutics | 2017 (Acquired) | $2.3 Billion | Immunotherapy/Oncology |
| Amylin Pharmaceuticals | 2012 (Acquired) | $7 Billion | Diabetes Treatment |
| Medarex | 2009 (Acquired) | $2.4 Billion | Immunotherapy/Oncology |
| Corden Pharma | 2009 (Acquired) | Private (Undisclosed) | Pharmaceutical Manufacturing |
| Padlock Therapeutics | 2016 (Acquired) | $600 Million | Immunology and Autoimmune Diseases |
| Turning Point Therapeutics | 2022 (Acquired) | $4.1 Billion | Targeted Cancer Therapy |
FAQs About Bristol-Myers Squibb
Q1: When was Bristol-Myers Squibb founded, and by whom?
A: Bristol-Myers Squibb was formed through the merger of Bristol-Myers Company, founded by William Bristol and John Myers in 1887, and Squibb Corporation, founded by Edward Robinson Squibb in 1858.
Q2: Who is the current CEO of Bristol-Myers Squibb?
A: The current CEO of Bristol-Myers Squibb is Giovanni Caforio, who has been leading the company since 2015.
Q3: What are the key therapeutic areas of Bristol-Myers Squibb?
A: BMS focuses on oncology, immunology, cardiovascular diseases, hematology, and autoimmune disorders.
Q4: What is the significance of Celgene’s acquisition by BMS?
A: The acquisition of Celgene in 2019 was one of the largest in pharmaceutical history, valued at $74 billion. This acquisition enhanced BMS’s portfolio, particularly in cancer and immune-related treatments.
Q5: Does Bristol-Myers Squibb offer any life-saving medications?
A: Yes, BMS offers several groundbreaking medications, including Opdivo (for cancer treatment) and Eliquis (for cardiovascular conditions), which have transformed the lives of millions of patients worldwide.
Q6: What is BMS’s role in cancer treatment?
A: BMS is a leader in cancer immunotherapy, developing innovative treatments such as Opdivo and Yervoy, which have revolutionized the treatment of various cancers.
